According to Blueprint Medicines 's latest financial reports the company's current earnings (TTM) are -$0.51 B. In 2022 the company made an earning of -$0.56 B an increase over its 2021 earnings that were of -$0.65 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.51 B | -8.38% |
2022 | -$0.56 B | -13.85% |
2021 | -$0.65 B | -304.94% |
2020 | $0.31 B | -189.97% |
2019 | -$0.35 B | 46.93% |
2018 | -$0.24 B | 59.76% |
2017 | -$0.15 B | 104.32% |
2016 | -$72.5 M | 37.38% |
2015 | -$52.77 M | 30.99% |
2014 | -$40.29 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pacific Biosciences
PACB | -$0.32 B | -37.12% | ๐บ๐ธ USA |
OPKO Health
OPK | -$0.19 B | -63.57% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | -$0.26 B | -49.51% | ๐บ๐ธ USA |
Isoray
ISR | -$10.9 M | -97.85% | ๐บ๐ธ USA |